Rgenta Therapeutics
PrivateLast Round
Series B
Oct 19, 2026
Total Funding Raised
$90M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Rgenta Therapeutics operates in Healthcare & Life Sciences and is based in Woburn, Massachusetts. Its latest recorded funding round was a Series A round in November 2022.
Rgenta Therapeutics is a biotechnology company that develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rgenta Therapeutics Comparables
Compare Rgenta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Accent Therapeutics | 88% | |
| Remix Therapeutics | 85% | |
| Arrakis Therapeutics | 84% |
For institutional investors. Book with your work email.
Rgenta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 19, 2026 | ||||
| Series A | Nov 29, 2022 | ||||
| Seed | May 25, 2021 | ||||
| Seed | Apr 2, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Rgenta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series A, Seed |
| Legend Star | Seed |
| Korea Investment Partners | Series A |
| Kaitai Capital | Seed, Series A |
| MPC | Series A, Seed |
| Boehringer Ingelheim Venture Fund | Series A, Seed |
| Lilly Asia Ventures | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 19, 2026
Raised $42M Series B round
- Apr 21, 2026
Phase 1a/b study data released for oral MYB splicing modulator RGT-61159.
For institutional investors. Book with your work email.
Rgenta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Rgenta Therapeutics's valuation, stock price, and market status.
Is Rgenta Therapeutics a public or private company?
Rgenta Therapeutics is a private company.
What is the current stock price of Rgenta Therapeutics?
Rgenta Therapeutics is a private company, so its shares have no public market price. Caplight tracks Rgenta Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rgenta Therapeutics worth (valuation)?
Valuation information for Rgenta Therapeutics is not publicly available.
Can I buy Rgenta Therapeutics stock?
Rgenta Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rgenta Therapeutics's last funding round?
Rgenta Therapeutics's most recent funding round was Series B on October 19, 2026.
Who are the main investors in Rgenta Therapeutics?
Key investors in Rgenta Therapeutics include Matrix, MPC, Boehringer Ingelheim Venture Fund, CICC Fund.
Will Rgenta Therapeutics IPO soon?
No public IPO plans have been announced for Rgenta Therapeutics.
How can I track Rgenta Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Rgenta Therapeutics's shares on secondary markets.